Beyond their use as research tools, over the last two decades, antibodies have become a critical component of many diagnostic assays. These assays have the potential to measure key biomarkers and provide clinicians with crucial insight to aid an effective diagnosis. Furthermore, using IVD assays as a companion diagnostic helps to screen patients and ensure that prescribed therapeutic agents will be efficacious for the specific disease variant. This can provide better clinical outcomes for the patient as well a more effective use of healthcare resources. As such IVD assays are an increasingly important part of clinical disease diagnosis, management and treatment selection. This is driving a rapid expansion of the companion diagnostics market, which is expected to reach $6 billion by 2025, according to industry data.